Melissa L. Danielson

Melissa L. Danielson

Auto-generated profile, based on publicly available information

Melissa L. Danielson

National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Pediatrics
Verified
Journal Article
Closed access
PDF file
BZBenjamin Zablotsky
Benjamin Zablotsky
LBLindsey I. Black
Lindsey I. Black
MMMatthew J. Maenner
Matthew J. Maenner
LSLaura A. Schieve
Laura A. Schieve
MDMelissa L. Danielson
Melissa L. Danielson
CBColeen A. Boyle
Coleen A. Boyle
OBJECTIVES: To study the national prevalence of 10 developmental disabilities in US children aged 3 to 17 years and explore changes over time by associated demographic and socioeconomic characteristics, using the National Health Interview Survey. METHODS: Data come from the 2009 to 2017 National Health Interview Survey, a nationally representative survey of the civilian noninstitutionalized population. Parents reported physician or other health care professional diagnoses of attention-deficit/hyperactivity disorder; autism spectrum disorder; blindness; cerebral palsy; moderate to profound hearing loss; learning disability; intellectual disability; seizures; stuttering or stammering; and other developmental delays. Weighted percentages for each of the selected developmental disabilities and any developmental disability were calculated and stratified by demographic and socioeconomic characteristics. RESULTS: From 2009 to 2011 and 2015 to 2017, there were overall significant increases in the prevalence of any developmental disability (16.2%–17.8%, P < .001), attention-deficit/hyperactivity disorder (8.5%–9.5%, P < .01), autism spectrum disorder (1.1%–2.5%, P < .001), and intellectual disability (0.9%–1.2%, P < .05), but a significant decrease for any other developmental delay (4.7%–4.1%, P < .05). The prevalence of any developmental disability increased among boys, older children, non-Hispanic white and Hispanic children, children with private insurance only, children with birth weight ≥2500 g, and children living in urban areas and with less-educated mothers. CONCLUSIONS: The prevalence of developmental disability among US children aged 3 to 17 years increased between 2009 and 2017. Changes by demographic and socioeconomic subgroups may be related to improvements in awareness and access to health care.

4 March 2016 in Journal of Clinical Child & Adolescent Psychology
Verified
Journal Article
Closed access
MDMelissa L. Danielson
Melissa L. Danielson
RBRebecca H. Bitsko
Rebecca H. Bitsko
RGReem M. Ghandour
Reem M. Ghandour
JHJoseph R. Holbrook
Joseph R. Holbrook
MKMichael D. Kogan
Michael D. Kogan
SBStephen J. Blumberg
Stephen J. Blumberg
The purpose of this study is to estimate the national prevalence of parent-reported attention deficit/hyperactivity disorder (ADHD) diagnosis and treatment among U.S. children 2–17 years of age using the 2016 National Survey of Children’s Health (NSCH). The NSCH is a nationally representative, cross-sectional survey of parents regarding their children’s health that underwent a redesign before the 2016 data collection. It included indicators of lifetime receipt of an ADHD diagnosis by a health care provider, whether the child currently had ADHD, and receipt of medication and behavioral treatment for ADHD. Weighted prevalence estimates were calculated overall and by demographic and clinical subgroups (n = 45,736). In 2016, an estimated 6.1 million U.S. children 2–17 years of age (9.4%) had ever received an ADHD diagnosis. Of these, 5.4 million currently had ADHD, which was 89.4% of children ever diagnosed with ADHD and 8.4% of all U.S. children 2–17 years of age. Of children with current ADHD, almost two thirds (62.0%) were taking medication and slightly less than half (46.7%) had received behavioral treatment for ADHD in the past year; nearly one fourth (23.0%) had received neither treatment. Similar to estimates from previous surveys, there is a large population of U.S. children and adolescents who have been diagnosed with ADHD by a health care provider. Many, but not all, of these children received treatment that appears to be consistent with professional guidelines, though the survey questions are limited in detail about specific treatment types received. The redesigned NSCH can be used to annually monitor diagnosis and treatment patterns for this highly prevalent and high-impact neurodevelopmental disorder.

1 January 2014 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Closed access
SVSusanna N. Visser
Susanna N. Visser
MDMelissa L. Danielson
Melissa L. Danielson
RBRebecca H. Bitsko
Rebecca H. Bitsko
JHJoseph R. Holbrook
Joseph R. Holbrook
MKMichael D. Kogan
Michael D. Kogan
SBStephen J. Blumberg
Stephen J. Blumberg

3 May 2024 in Journal of Clinical Child & Adolescent Psychology
Verified
Journal Article
Closed access
MDMelissa L. Danielson
Melissa L. Danielson
ACAngelika H. Claussen
Angelika H. Claussen
RBRebecca H. Bitsko
Rebecca H. Bitsko
SKSamuel M. Katz
Samuel M. Katz
KNKimberly Newsome
Kimberly Newsome
RGReem Ghandour
Reem Ghandour

21 December 2018 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
RCRobyn A. Cree
Robyn A. Cree
RBRebecca H. Bitsko
Rebecca H. Bitsko
LRLara R. Robinson
Lara R. Robinson
JHJoseph R. Holbrook
Joseph R. Holbrook
MDMelissa L. Danielson
Melissa L. Danielson
GPGeorgina Peacock
Georgina Peacock
Parent-reported data from 2016 indicated that a higher percentage of children in lower-income households had ever received a diagnosis of a mental, behavioral, or developmental disorder and a lower percentage had seen a health care provider in the previous year, compared with children in higher-income households. Most children in lower-income households were in families receiving public assistance benefits.

23 April 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AWAngela Werner
Angela Werner
EKEmilia H. Koumans
Emilia H. Koumans
KCKevin Chatham-Stephens
Kevin Chatham-Stephens
PSPhillip P. Salvatore
Phillip P. Salvatore
CAChristina Armatas
Christina Armatas
SRSarah Reagan-Steiner
Sarah Reagan-Steiner
As of January 7, 2020, a total of 2558 hospitalized patients with nonfatal cases and 60 patients with fatal cases of e-cigarette, or vaping, product use–associated lung injury (EVALI) had been reported to the Centers for Disease Control and Prevention (CDC). In a national study, we compared the characteristics of patients with fatal cases of EVALI with those of patients with nonfatal cases to improve the ability of clinicians to identify patients at increased risk for death from the condition. Health departments reported cases of EVALI to the CDC and included, when available, data from medical-record abstractions and patient interviews. Analyses included all the patients with fatal or nonfatal cases of EVALI that were reported to the CDC as of January 7, 2020. We also present three case reports of patients who died from EVALI to illustrate the clinical characteristics common among such patients. Most of the patients with fatal or nonfatal cases of EVALI were male (32 of 60 [53%] and 1666 of 2498 [67%], respectively). The proportion of patients with fatal or nonfatal cases was higher among those who were non-Hispanic white (39 of 49 [80%] and 1104 of 1818 [61%], respectively) than among those in other race or ethnic groups. The proportion of patients with fatal cases was higher among those 35 years of age or older (44 of 60 [73%]) than among those younger than 35 years, but the proportion with nonfatal cases was lower among those 35 years of age or older (551 of 2514 [22%]). Among the patients who had an available medical history, a higher proportion of those with fatal cases than those with nonfatal cases had a history of asthma (13 of 57 [23%] vs. 102 of 1297 [8%]), cardiac disease (26 of 55 [47%] vs. 115 of 1169 [10%]), or a mental health condition (32 of 49 [65%] vs. 575 of 1398 [41%]). A total of 26 of 50 patients (52%) with fatal cases had obesity. Half the patients with fatal cases (25 of 54 [46%]) were seen in an outpatient setting before hospitalization or death. Chronic conditions, including cardiac and respiratory diseases and mental health conditions, were common among hospitalized patients with EVALI.